alphamab oncology-凯发88

english 凯发88-凯发vip-娱乐凯发app下载中文繁体

alphamab oncology and 3dmedicines entered into a licensing agreement with glenmark for kn035

the notable advantages of envafolimab in terms of safety, convenience, and compliance position it as a competitive product
alphamab oncology announced innovative bispecific antibody coupling drug jskn016 clinical study accepted by cde

jskn016 is a bispecific antibody conjugated drug (adc) targeting her3 and trop2
alphmab's novel subcutaneous anti-her2 bispecific adc jskn033 approved for clinical studies in australia

jskn033 is a subcutaneous injection compound consisting of jskn003 and envafolimab

vision, mission and core values

our mission : to make cancer manageable and curable

our vision : to develop differentiated, clinically valuable and globally competitive new drugs

our core values : innovation, ownership, integrity, quality, growth

learn more

proprietary platforms
innovative pipeline
biologics manufacturing

world-class bispecific, adc and mix-mab platforms

in complex diseases, such as cancer and viral infection, multiple signaling pathways or mechanisms are involved. alphamab oncology has developed several proprietary technical approaches to provide innovative solutions to address this growing trend in the development of modern biotherapeutics.

learn more

innovative pipeline with significant potential and mitigated development risk

leveraging its proprietary technology platforms, alphamab oncology has developed an exciting pipeline with clear differentiation and global competitiveness.

learn more

state of art cgmp manufacturing with a solid track record

the production of biologics, such as antibody drugs, is a complex, lengthy and costly process. we have established our own cgmp production facilities with strong in house expertise to address the manufacturing issues.

learn more

alphamab oncology-凯发88

company

overview

board of directors

partnering

core competence

technology

bispecific

proprietary adc platform

mix-mab

publications

pipeline

overview

envafolimab(kn035)

kn046

kn026

jskn003

kn026 kn046

kn019

investors

information disclosure

corporate governance

stock information

ir contacts

email subscription

news

press release

media report

career

corporate culture

job opportunities

contact us

vision, mission and core values

our mission : to make cancer manageable and curable

our vision : to develop differentiated, clinically valuable and globally competitive new drugs

our core values : innovation, ownership, integrity, quality, growth

world-class bispecific, adc and mix-mab platforms

in complex diseases, such as cancer and viral infection, multiple signaling pathways or mechanisms are involved. alphamab oncology has developed several proprietary technical approaches to provide innovative solutions to address this growing trend in the development of modern biotherapeutics.

innovative pipeline with significant potential and mitigated development risk

leveraging its proprietary technology platforms, alphamab oncology has developed an exciting pipeline with clear differentiation and global competitiveness.

state of art cgmp manufacturing with a solid track record

the production of biologics, such as antibody drugs, is a complex, lengthy and costly process. we have established our own cgmp production facilities with strong in house expertise to address the manufacturing issues.

alphamab oncology-凯发88

vision, mission and core values

our mission : to make cancer manageable and curable our vision : to develop differentiated, clinically valuable and globally competitive new drugs our core values : innovation, ownership, integrity, quality, growth

world-class bispecific, adc and mix-mab platforms

in complex diseases, such as cancer and viral infection, multiple signaling pathways or mechanisms are involved. alphamab oncology has developed several proprietary technical approaches to provide innovative solutions to address this growing trend in the development of modern biotherapeutics.

innovative pipeline with significant potential and mitigated development risk

leveraging its proprietary technology platforms, alphamab oncology has developed an exciting pipeline with clear differentiation and global competitiveness.

state of art cgmp manufacturing with a solid track record

the production of biologics, such as antibody drugs, is a complex, lengthy and costly process. we have established our own cgmp production facilities with strong in house expertise to address the manufacturing issues.

our mission : to make cancer manageable and curable

our vision : to develop differentiated, clinically valuable and globally competitive new drugs

our core values : innovation, ownership, integrity, quality, growth